Physician-scientist David Solit was interviewed about exceptional responders, patients who defy all expectations by responding dramatically to a drug t...
Event
Every year, MSK gives high school students and their teachers the opportunity to learn about cutting-edge biomedical research from our scientists.
Feature
Memorial Sloan Kettering’s vision is nothing less than to revolutionize the treatment of cancer. Learn about some of the ways we’re doing it.
Physician-scientist David Solit discussed the use of sophisticated DNA sequencing technology to determine why some patients have exceptional responses ...
Announcement
With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer.
Profile
David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.
Physician-scientist David Solit commented on exceptional responders, patients who respond to treatments when others typically do not....
Cancer researcher David Solit was profiled about his research to uncover why certain patients respond well to drugs that did not help others....
Feature
Research at Memorial Sloan Kettering will benefit from renewed support for The Starr Cancer Consortium and the Tri-Institutional Stem Cell Initiative totaling $105 million.
Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug vemurafenib.
Honors
Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.
Media Advisory
Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib.
Cancer researcher and Human Oncology and Pathogenesis Program member David Solit spoke about a study he led that sequenced the entire genome of a patie...
In the Clinic
A prominent research grant will enable MSK doctors and scientists to advance the treatment of bladder cancer.
